In the latest close session, Merck (MRK) was down 3.31% at $78.28. This change lagged the S&P 500's daily loss of 0.84%. Meanwhile, the Dow lost 0.7%, and the Nasdaq, a tech-heavy index, lost 0.91%.

In this video, Susana M. Campos, MD, MPH, discusses results from a phase 2 trial of pembrolizumab and lenvatinib for patients with recurrent or persistent clear-cell ovarian cancer.Findings from the ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

Merck & Co., Inc. (NYSE:MRK) is one of the 15 best stocks to invest in for an 18 year old. On June 10, Cantor Fitzgerald ...

The lawmakers accuse Pfizer, Merck, J&J, AbbVie and Amgen of paying little to nothing in federal taxes despite generating ...

Fat steers and heifers filled the pens at the Finney County Fairgrounds in the early morning hours of June 3, waiting to be ...

The IPO comes just a few weeks after Caris raised $168 million in a private financing round that took the total raised by the ...

AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a ...

That challenge, of finding or building good, useable data sets, is also one of the biggest differentiators in an increasingly ...

The biopharma company—whose US headquarters is in Atlanta—will be building a new biologics manufacturing facility in a city ...

Biogen has emerged as a potential front-runner at the Cannes Lions International Festival of Creativity, snagging four spots ...